West Pharmaceutical Services, Inc

West Pharmaceutical Services is a U.S.-based manufacturer of containment and delivery systems used with injectable drugs and healthcare products. Its business spans proprietary packaging and drug-delivery components, contract manufacturing, analytical lab services, and integrated solutions for pharmaceutical, biologic, diagnostic, and medical device customers worldwide.

24,6 %

35,9 %

16,1 %

+6,3 %

3.02

2.34

— West Pharmaceutical Services, Inc
%
Proprietary Products65% Proprietary packaging, containment, and drug-delivery components for injectable therapies.
Contract-Manufactured Products35% Design, manufacture, and automated assembly of complex devices and components for customers.

West sells to pharmaceutical, biologic, generic, diagnostic, and medical device companies that need components or...

  • Biologic pharmaceutical companiesprimary

    Buy containment and delivery systems for injectable biologics and specialty therapies; they value quality, compatibility, and regulatory support.

  • Generic and traditional pharmaceutical companiesprimary

    Buy packaging components, transfer systems, and delivery devices for injectable medicines and line integration.

  • Diagnostic and medical device companiessecondary

    Buy contract-manufactured components and assembled devices for further processing or end-use products.

  • Large strategic accountsprimary

    High-volume customers that purchase across both proprietary and contract-manufacturing segments.

West operates as a global business with manufacturing, sales, and support activities across the United States and many...

  • Global manufacturing and sales footprint across major pharmaceutical markets
  • U.S. base with significant operations and cash held outside the U.S.
  • Collaborations in Japan and Mexico support technology sharing and market access
  • International exposure creates tariff, customs, and currency risk
  • Local manufacturing capability helps serve multinational customers

West’s strategy centers on being a full-service supplier of high-quality injectable drug containment and delivery...

01
Broaden integrated drug-delivery solutionsmedium-term

Customers want suppliers that can combine packaging, device, and technical support in one platform.

02
Strengthen global manufacturing flexibilitymedium-term

Multinational customers value supply continuity and local production options.

03
Advance proprietary delivery technologieslong-term

Innovation helps defend against commoditization and alternative delivery formats.

04
Improve automated assembly capabilitiesshort-term

Automation supports complex device production and competitive cost structure.

West faces customer concentration, pricing pressure, and intense competition across both proprietary components and...

high

Customer concentration

Ten customers represented a large share of consolidated sales, so account loss or volume shifts can materially affect revenue.

Scope
One customer exceeded 10% of sales
Materiality
high
high

Pricing pressure

Large pharmaceutical customers and competitors can force lower prices or tougher contract terms.

Scope
Both proprietary and contract-manufacturing segments
Materiality
high
high

Shift away from injectable therapies

The business depends on products delivered by injection; alternative delivery methods could reduce demand.

Scope
GLP-1 and other injectable drug programs
Materiality
high
medium

International trade and regulatory exposure

Operations span multiple countries, creating exposure to tariffs, customs controls, and local compliance requirements.

Scope
Global manufacturing and sales network
Materiality
medium
medium

Impairment risk on goodwill and long-lived assets

Valuations depend on future cash flows, product demand, and innovation success.

Scope
Reporting units and manufacturing assets
Materiality
medium
Revenue recognition and shipment timing
Quarterly comparability
Goodwill impairment
Could create material non-cash charges
Long-lived asset impairment
May affect operating results and asset values
Inventory and purchase commitments
Working capital and supply-chain exposure
Derivatives and foreign currency
Earnings and balance-sheet volatility

: 11/08/2026